Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

75 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial.
Ivashchenko AA, Dmitriev KA, Vostokova NV, Azarova VN, Blinow AA, Egorova AN, Gordeev IG, Ilin AP, Karapetian RN, Kravchenko DV, Lomakin NV, Merkulova EA, Papazova NA, Pavlikova EP, Savchuk NP, Simakina EN, Sitdekov TA, Smolyarchuk EA, Tikhomolova EG, Yakubova EV, Ivachtchenko AV. Ivashchenko AA, et al. Among authors: ivachtchenko av. Clin Infect Dis. 2021 Aug 2;73(3):531-534. doi: 10.1093/cid/ciaa1176. Clin Infect Dis. 2021. PMID: 32770240 Free PMC article. Clinical Trial.
Reply to Krishna Prabha et al.
Ivashchenko AA, Savchuk NP, Yakubova EV, Ivachtchenko AV. Ivashchenko AA, et al. Among authors: ivachtchenko av. Clin Infect Dis. 2021 Aug 2;73(3):e848-e849. doi: 10.1093/cid/ciaa1606. Clin Infect Dis. 2021. PMID: 33099607 No abstract available.
Effect of Aprotinin and Avifavir® Combination Therapy for Moderate COVID-19 Patients.
Ivashchenko AA, Azarova VN, Egorova AN, Karapetian RN, Kravchenko DV, Krivonos NV, Loginov VG, Poyarkov SV, Merkulova EA, Rosinkova OS, Savchuk NP, Topr MA, Simakina EN, Yakubova EV, Ivachtchenko AV. Ivashchenko AA, et al. Among authors: ivachtchenko av. Viruses. 2021 Jun 27;13(7):1253. doi: 10.3390/v13071253. Viruses. 2021. PMID: 34199134 Free PMC article.
Safety and efficacy of aviandr in patients with generalized anxiety disorder: A multicenter, randomized, double-blind, placebo-controlled, dose-finding, pilot study.
Ivashchenko AA, Morozova MA, Vostokova NV, Beniashvily AG, Bukhanovskaya OA, Burminskiy DS, Egorova AN, Gluskina LY, Gorchakov DS, Karapetian RN, Kasimova LN, Kravchenko DV, Lepilkina TA, Merkulova EA, Mitkin OD, Penchul NA, Potanin SS, Rupchev GE, Ivachtchenko AV. Ivashchenko AA, et al. Among authors: ivachtchenko av. J Psychiatr Res. 2021 Nov;143:436-444. doi: 10.1016/j.jpsychires.2021.10.008. Epub 2021 Oct 11. J Psychiatr Res. 2021. PMID: 34656876 Clinical Trial.
The Efficacy of Aprotinin Combinations with Selected Antiviral Drugs in Mouse Models of Influenza Pneumonia and Coronavirus Infection Caused by SARS-CoV-2.
Ivashchenko AA, Zagribelnyy BA, Ivanenkov YA, Ivashchenko IA, Karapetian RN, Kravchenko DV, Savchuk NP, Yakubova EV, Ivachtchenko AV. Ivashchenko AA, et al. Among authors: ivachtchenko av. Molecules. 2022 Aug 5;27(15):4975. doi: 10.3390/molecules27154975. Molecules. 2022. PMID: 35956925 Free PMC article.
Synthesis, inhibitory activity and oral dosing formulation of AV5124, the structural analogue of influenza virus endonuclease inhibitor baloxavir.
Ivashchenko AA, Mitkin OD, Jones JC, Nikitin AV, Koryakova AG, Karapetian RN, Kravchenko DV, Mochalov SV, Ryakhovskiy AA, Aladinskiy V, Leneva IA, Falynskova IN, Glubokova EA, Govorkova EA, Ivachtchenko AV. Ivashchenko AA, et al. Among authors: ivachtchenko av. J Antimicrob Chemother. 2021 Mar 12;76(4):1010-1018. doi: 10.1093/jac/dkaa524. J Antimicrob Chemother. 2021. PMID: 33367751 Free PMC article.
Crystal structure, Hirshfeld analysis and a mol-ecular docking study of a new inhibitor of the Hepatitis B virus (HBV): ethyl 5-methyl-1,1-dioxo-2-{[5-(pentan-3-yl)-1,2,4-oxa-diazol-3-yl]meth-yl}-2H-1,2,6-thia-diazine-4-carboxyl-ate.
Ivachtchenko AV, Kovalenko SM, Kravchenko DV, Mitkin OD, Ivanov VV, Langer T. Ivachtchenko AV, et al. Acta Crystallogr E Crystallogr Commun. 2020 Jan 1;76(Pt 1):12-17. doi: 10.1107/S2056989019015986. eCollection 2020 Jan 1. Acta Crystallogr E Crystallogr Commun. 2020. PMID: 31921445 Free PMC article.
Natural products as templates for bioactive compound libraries: part 2. Novel modifications of vasicine (peganine) core via efficient and regioselective generation of 3-lithiodeoxyvasicine and its stereoselective addition to aliphatic ketones section sign.
Shevyakov SV, Davydova OI, Kiselyov AS, Kravchenko DV, Ivachtchenko AV, Krasavin M. Shevyakov SV, et al. Among authors: ivachtchenko av. Nat Prod Res. 2006 Jul 20;20(9):871-81. doi: 10.1080/14786410500480993. Nat Prod Res. 2006. PMID: 16753926
Novel aryl and heteroaryl substituted N-[3-(4-phenylpiperazin-1-yl)propyl]-1,2,4-oxadiazole-5-carboxamides as selective GSK-3 inhibitors.
Koryakova AG, Ivanenkov YA, Ryzhova EA, Bulanova EA, Karapetian RN, Mikitas OV, Katrukha EA, Kazey VI, Okun I, Kravchenko DV, Lavrovsky YV, Korzinov OM, Ivachtchenko AV. Koryakova AG, et al. Among authors: ivachtchenko av. Bioorg Med Chem Lett. 2008 Jun 15;18(12):3661-6. doi: 10.1016/j.bmcl.2007.11.121. Epub 2007 Dec 5. Bioorg Med Chem Lett. 2008. PMID: 18502121
Discovery of novel highly potent hepatitis C virus NS5A inhibitor (AV4025).
Ivachtchenko AV, Mitkin OD, Yamanushkin PM, Kuznetsova IV, Bulanova EA, Shevkun NA, Koryakova AG, Karapetian RN, Bichko VV, Trifelenkov AS, Kravchenko DV, Vostokova NV, Veselov MS, Chufarova NV, Ivanenkov YA. Ivachtchenko AV, et al. J Med Chem. 2014 Sep 25;57(18):7716-30. doi: 10.1021/jm500951r. Epub 2014 Sep 9. J Med Chem. 2014. PMID: 25148100
75 results